Lacosamide Medical Valley: Uses, Dosage & Side Effects

What Is Lacosamide Medical Valley and What Is It Used For?

Lacosamide Medical Valley contains the active ingredient lacosamide, a functionalized amino acid that was specifically developed as an antiepileptic drug. Unlike many other antiepileptic medications that were discovered through serendipity or repurposed from other therapeutic areas, lacosamide was designed through a systematic medicinal chemistry program aimed at identifying compounds with novel mechanisms of action against seizures. The result is a medication that works differently from most other available antiepileptics, offering an important therapeutic option for patients whose seizures are not adequately controlled by existing treatments.

The primary therapeutic indication for Lacosamide Medical Valley is the treatment of focal seizures (previously called partial-onset seizures) with or without secondary generalization in adults and adolescents aged 4 years and older. Focal seizures originate in a specific region of one cerebral hemisphere and are the most common type of seizure in adults with epilepsy, accounting for approximately 60% of all epilepsy cases. These seizures can manifest in a wide variety of ways depending on the brain region involved, ranging from brief episodes of altered awareness to involuntary movements, sensory disturbances, or automatic behaviors. When a focal seizure spreads to involve both cerebral hemispheres, it becomes secondarily generalized, typically manifesting as a tonic-clonic (convulsive) seizure.

Lacosamide exerts its antiepileptic effect through a novel mechanism of action: it selectively enhances the slow inactivation of voltage-gated sodium channels. To understand why this is significant, it is helpful to know that sodium channels exist in three states — resting, open, and inactivated. Most traditional sodium channel-blocking antiepileptics (such as carbamazepine, phenytoin, and lamotrigine) primarily target fast inactivation, where the channel rapidly transitions from the open to the inactivated state. Lacosamide, in contrast, enhances slow inactivation, a separate and slower process that shifts the channel into a more prolonged inactivated state. By promoting this slow inactivation, lacosamide selectively reduces the ability of neurons to fire rapidly and repetitively — a hallmark of epileptic activity — without significantly affecting normal neuronal function. This unique mechanism provides a rationale for combining lacosamide with other sodium channel blockers that target fast inactivation, as their mechanisms of action are complementary rather than redundant.

In addition to its effects on sodium channels, lacosamide has been shown to bind to collapsin response mediator protein-2 (CRMP-2), a protein involved in neuronal growth and development. The clinical significance of this interaction in the context of epilepsy treatment is not yet fully understood, but it may contribute to neuroprotective effects or influence the long-term course of epilepsy.

Lacosamide can be used as monotherapy (the only antiepileptic drug a patient takes) or as adjunctive therapy (added to one or more existing antiepileptic medications). The efficacy of lacosamide has been established through several large, randomized, double-blind, placebo-controlled clinical trials in both adult and pediatric populations. In pivotal adjunctive therapy trials involving over 1,300 adults with uncontrolled focal seizures despite treatment with one to three other antiepileptic drugs, lacosamide at doses of 200 mg/day and 400 mg/day significantly reduced seizure frequency compared with placebo. The 50% responder rate (the proportion of patients experiencing at least a 50% reduction in seizure frequency) was approximately 33–41% for lacosamide 200 mg/day and 38–40% for 400 mg/day, compared with 18–26% for placebo.

The monotherapy indication was established through a landmark historical-controlled conversion-to-monotherapy trial and a non-inferiority trial comparing lacosamide with carbamazepine extended-release in newly diagnosed epilepsy patients. In the non-inferiority study, lacosamide demonstrated comparable efficacy to carbamazepine, with similar proportions of patients achieving sustained seizure freedom over 6 and 12 months.

Lacosamide Medical Valley is a generic equivalent of the originator product Vimpat (UCB Pharma). As a generic medication, it has demonstrated bioequivalence to Vimpat, meaning that it is absorbed at the same rate and to the same extent as the reference product. Patients can expect the same therapeutic effects and safety profile. The availability of generic lacosamide provides an important option for improving access to this effective antiepileptic medication at a reduced cost, which is particularly relevant given that epilepsy treatment is typically lifelong.

What Should You Know Before Taking Lacosamide Medical Valley?

Contraindications

Lacosamide Medical Valley must not be used in patients with known hypersensitivity to the active substance lacosamide or to any of the excipients contained in the formulation. Hypersensitivity reactions, though uncommon, can include rash, urticaria (hives), angioedema, and in rare cases, multi-organ hypersensitivity reactions with systemic features such as fever, rash, lymphadenopathy, liver function abnormalities, and eosinophilia (Drug Reaction with Eosinophilia and Systemic Symptoms — DRESS syndrome). If a hypersensitivity reaction occurs, lacosamide should be discontinued immediately.

Lacosamide is also contraindicated in patients with known second-degree or third-degree atrioventricular (AV) block. This is because lacosamide has been shown to cause dose-dependent prolongation of the PR interval on the electrocardiogram, and administration to patients with pre-existing high-degree AV block could worsen cardiac conduction and potentially lead to complete heart block or other serious cardiac arrhythmias.

Warnings and Precautions

Before starting Lacosamide Medical Valley, your doctor should be informed about the following conditions and considerations:

• Cardiac conduction disorders: Lacosamide causes dose-dependent PR interval prolongation. Patients with underlying cardiac conduction problems (such as first-degree AV block, sick sinus syndrome without a pacemaker), those taking medications that prolong the PR interval (such as beta-blockers, calcium channel blockers, or digoxin), or those with severe cardiac disease (including a history of myocardial infarction or heart failure) should have an ECG performed before starting treatment and be closely monitored. Cases of second-degree and third-degree AV block, bradycardia, and atrial fibrillation/flutter have been reported during post-marketing surveillance.
• Dizziness and ataxia: Dizziness and balance problems are among the most common side effects of lacosamide and may increase the risk of falls, particularly in elderly patients. Patients should be advised to exercise caution during activities requiring alertness and coordination until they understand how lacosamide affects them.
• Suicidal ideation: A pooled analysis of clinical trials involving 11 different antiepileptic drugs demonstrated a small but statistically significant increase in the risk of suicidal ideation and behavior (approximately 0.43% for antiepileptic drugs versus 0.24% for placebo). This risk applies to all antiepileptic drugs, including lacosamide. Patients should be monitored for signs of depression, suicidal thoughts, or unusual changes in mood or behavior, especially during the initial months of therapy and after dose adjustments.
• Hepatic impairment: Patients with mild to moderate hepatic impairment may achieve higher plasma levels of lacosamide, and a dose reduction may be necessary. In severe hepatic impairment, a maximum dose of 300 mg/day is recommended, and titration should proceed with caution.
• Renal impairment: No dose adjustment is generally required for mild to moderate renal impairment. In severe renal impairment (creatinine clearance ≤30 mL/min) and in patients requiring hemodialysis, a maximum dose of 300 mg/day is recommended. On dialysis days, a supplementary dose of up to 50% of the divided daily dose may be administered after the hemodialysis session.

Pregnancy and Breastfeeding

Lacosamide should not be used during pregnancy unless clearly necessary and only if the potential benefit to the mother justifies the potential risk to the fetus. There are limited data on the use of lacosamide in pregnant women. Animal studies have shown reproductive toxicity, including increased post-implantation loss and reduced fetal and pup body weight at maternally toxic doses. As with all antiepileptic drugs, there is a general concern about potential teratogenic effects, and women of childbearing potential should use effective contraception during treatment.

If a woman becomes pregnant or plans to become pregnant while taking lacosamide, she should contact her doctor immediately. It is critically important not to discontinue antiepileptic medication abruptly, as this can trigger breakthrough seizures or status epilepticus, which poses significant risks to both the mother and the fetus. Any changes to the treatment regimen during pregnancy should be made gradually and under close medical supervision. Women taking antiepileptic drugs during pregnancy are encouraged to register with pregnancy exposure registries, which collect data to help understand the effects of these medications on pregnancy outcomes.

It is not known whether lacosamide or its metabolites are excreted in human breast milk. Animal studies have shown that lacosamide is excreted in milk. A risk to the breastfed infant cannot be excluded. The decision whether to continue or discontinue breastfeeding or to continue or discontinue lacosamide therapy should be made in consultation with the prescribing physician, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.

Driving and Operating Machinery

Lacosamide may have a moderate influence on the ability to drive and use machines. Treatment with lacosamide has been associated with dizziness, blurred vision, diplopia (double vision), and somnolence (drowsiness), all of which could impair the ability to drive or operate heavy machinery. Patients are advised not to drive or engage in other potentially hazardous activities until they have sufficient experience on lacosamide to gauge whether it affects their ability to perform these activities. Additionally, many jurisdictions have specific regulations regarding driving with a diagnosis of epilepsy, and patients should consult their doctor and local guidelines about fitness to drive.

How Does Lacosamide Medical Valley Interact with Other Drugs?

Lacosamide has a relatively simple pharmacokinetic profile that limits its potential for drug interactions. It is primarily metabolized by the cytochrome P450 enzyme CYP2C19, with CYP2C9, CYP3A4, and other isoenzymes playing minor roles. Approximately 40% of an oral dose of lacosamide is excreted unchanged in the urine, and only about 30% is excreted as the inactive O-desmethyl metabolite. Lacosamide does not significantly inhibit or induce major CYP enzymes at therapeutic concentrations, which means it is unlikely to substantially alter the metabolism of other drugs. Protein binding is low (less than 15%), further reducing the potential for displacement interactions.

However, certain drug interactions do merit attention. Since lacosamide is partially metabolized by CYP2C19, co-administration with strong CYP2C19 inhibitors (such as fluconazole or fluvoxamine) may lead to increased lacosamide plasma levels, potentially increasing the risk of side effects. Conversely, strong enzyme inducers such as carbamazepine, phenytoin, phenobarbital, and rifampicin can increase the metabolism of lacosamide, potentially reducing its plasma levels and efficacy. Population pharmacokinetic analyses from clinical trials have shown that co-administration with carbamazepine or phenytoin can reduce lacosamide plasma levels by approximately 25%, although this reduction was not considered clinically significant in most cases. Nevertheless, in some patients, particularly those on higher doses of enzyme-inducing antiepileptics, the clinical significance of this interaction may warrant dose adjustment of lacosamide.

An important pharmacodynamic interaction exists with other drugs that can prolong the PR interval on the ECG. When lacosamide is used in combination with PR-prolonging medications (such as beta-blockers, certain calcium channel blockers, or digoxin), the risk of AV block and bradycardia may be increased. An ECG is recommended before starting lacosamide in patients already taking such medications, and clinical monitoring is advisable.

Importantly, lacosamide does not affect the pharmacokinetics of commonly used oral contraceptives (ethinylestradiol and levonorgestrel), nor does it affect the pharmacokinetics of warfarin, metformin, digoxin, or omeprazole. This favorable interaction profile makes lacosamide a practical choice for patients who take multiple medications, including women of childbearing potential who use hormonal contraception — a clinically important advantage over enzyme-inducing antiepileptics such as carbamazepine or phenytoin, which can reduce the effectiveness of hormonal contraceptives.

Alcohol may enhance the central nervous system depressant effects of lacosamide, including dizziness, drowsiness, and impaired coordination. Patients should be advised to limit or avoid alcohol consumption during treatment. Similarly, caution should be exercised when lacosamide is used concomitantly with other CNS depressants, including benzodiazepines, opioids, and sedating antihistamines.

What Is the Correct Dosage of Lacosamide Medical Valley?

Lacosamide Medical Valley should always be taken exactly as prescribed by your doctor. The recommended dosing regimen involves a gradual titration from a low starting dose to the maintenance dose, which helps minimize dose-related side effects such as dizziness, nausea, and double vision. The film-coated tablets are taken orally, twice daily (morning and evening), at approximately the same times each day. Tablets can be taken with or without food and should be swallowed whole with a glass of water.

Adults and Adolescents (Weighing 50 kg or More)

The recommended starting dose is 50 mg twice daily (100 mg/day). After one week, the dose can be increased to 100 mg twice daily (200 mg/day). Depending on response and tolerability, the dose can be further increased by increments of 50 mg twice daily at weekly intervals up to the maximum recommended dose. For adjunctive therapy, the recommended maintenance dose is 200–400 mg/day. For monotherapy, the maintenance dose is 200–600 mg/day. Your doctor will determine the optimal dose based on your seizure control and tolerance of side effects.

In situations where rapid loading is required (for example, when switching from intravenous lacosamide to oral tablets), some clinicians may use a loading dose of 200 mg followed by the maintenance dose 12 hours later. However, this approach should only be used under medical supervision as it may be associated with a higher incidence of CNS side effects such as dizziness.

Children and Adolescents (Weighing Less Than 50 kg, Aged 4 Years and Older)

For children and adolescents weighing less than 50 kg, dosing is based on body weight. The recommended starting dose is 1 mg/kg twice daily (2 mg/kg/day), which is then titrated at weekly intervals by 1 mg/kg twice daily to the recommended maintenance dose of 3–6 mg/kg twice daily (6–12 mg/kg/day). The maximum recommended dose is 6 mg/kg twice daily (12 mg/kg/day), not exceeding 400 mg/day. As Lacosamide Medical Valley 50 mg tablets may not allow precise weight-based dosing in all pediatric patients, an oral solution formulation (available under the brand name Vimpat) may be more appropriate for younger children who require precise dose titration.

Elderly Patients

No dose reduction is generally required solely based on age. However, elderly patients may be more susceptible to side effects such as dizziness, falls, and cardiac conduction abnormalities. Age-related decline in renal function should also be considered. In elderly patients, dose titration should proceed carefully, and clinical monitoring should be more frequent, particularly regarding cardiac parameters. An ECG is recommended before initiating treatment in elderly patients.

Missed Dose

If you forget to take a dose, take it as soon as you remember, unless it is almost time for the next dose. In that case, skip the missed dose and take the next dose at the usual time. Do not take a double dose to make up for a missed dose. Maintaining consistent dosing is important for seizure control. If you frequently forget doses, consider using a pill organizer, mobile phone reminders, or setting alarms to help you remember.

Overdose

If you have taken more lacosamide than prescribed, seek medical attention immediately. Symptoms of overdose may include dizziness, nausea, vomiting, seizures (paradoxically), and cardiac conduction abnormalities (PR prolongation, AV block). In clinical experience, the highest single accidental overdose reported was 12,000 mg, which was associated with coma requiring intensive care. There is no specific antidote for lacosamide overdose. Treatment is supportive and may include gastric decontamination and symptomatic management. Lacosamide can be effectively removed by hemodialysis (approximately 50% is removed in a 4-hour session), which may be considered in cases of severe overdose.

What Are the Side Effects of Lacosamide Medical Valley?

Like all medicines, Lacosamide Medical Valley can cause side effects, although not everybody gets them. The side effects of lacosamide are generally dose-dependent, meaning they are more likely to occur and more pronounced at higher doses. Many of the common side effects, particularly dizziness and nausea, tend to improve during the initial weeks of treatment as the body adjusts to the medication. The gradual dose titration schedule recommended for lacosamide is specifically designed to minimize these dose-related adverse effects.

In clinical trials, the overall discontinuation rate due to adverse events was approximately 8% for lacosamide 200 mg/day, 17% for 400 mg/day, and 29% for 600 mg/day (the latter is above the maximum recommended dose for adjunctive therapy), compared with approximately 5% for placebo. The most common adverse events leading to discontinuation were dizziness, nausea, vomiting, diplopia, and coordination abnormalities.

The dizziness associated with lacosamide deserves particular attention, as it is the most frequently reported side effect and the most common reason for dose reduction or treatment discontinuation. In clinical trials, dizziness was reported by approximately 31% of patients receiving lacosamide 200 mg/day and 53% at 400 mg/day, compared with 8% for placebo. However, it is important to note that dizziness was generally transient, mild to moderate in severity, and often diminished with continued treatment or dose reduction.

Cardiac effects are among the most clinically significant potential adverse effects of lacosamide. The drug has a dose-dependent effect on cardiac conduction, specifically causing prolongation of the PR interval on the ECG. While PR prolongation is usually asymptomatic and does not require treatment modification, in some patients it can progress to higher degrees of AV block, particularly when lacosamide is combined with other PR-prolonging drugs or in patients with pre-existing cardiac conduction abnormalities. Patients should be advised to seek medical attention if they experience symptoms suggestive of cardiac conduction disturbances, such as a slow or irregular pulse, lightheadedness, or fainting episodes.

Serious dermatological reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported in rare cases during post-marketing surveillance. These are potentially life-threatening conditions that typically present with fever, rash, and involvement of multiple organ systems. If a patient develops a rash with systemic symptoms during lacosamide treatment, the drug should be immediately discontinued, and the patient should seek emergency medical care.

How Should You Store Lacosamide Medical Valley?

Proper storage of medications is essential to ensure their safety and effectiveness throughout their shelf life. Lacosamide Medical Valley film-coated tablets should be stored at room temperature, not exceeding 30°C (86°F). There is no need to refrigerate the tablets. The medication should be kept in its original packaging (blister pack or bottle) to protect it from moisture and light.

As with all medications, Lacosamide Medical Valley should be kept out of the sight and reach of children. The tablets should be stored in a secure location, as accidental ingestion by children could lead to serious adverse effects. Do not use this medicine after the expiry date which is stated on the carton and blister pack. The expiry date refers to the last day of that month.

Do not dispose of medicines via household waste or wastewater. Return any unused medication or medication that has passed its expiry date to your pharmacist for safe disposal. These measures help protect the environment and prevent accidental exposure. If you notice any change in the appearance of the tablets (discoloration, crumbling, or unusual odor), do not use them and consult your pharmacist.

What Does Lacosamide Medical Valley Contain?

Each Lacosamide Medical Valley 50 mg film-coated tablet contains 50 mg of lacosamide as the active substance. Lacosamide is a white to off-white crystalline powder with the chemical name (R)-2-acetamido-N-benzyl-3-methoxypropionamide. It has a molecular formula of C₁₃H₁₈N₂O₃ and a molecular weight of 250.3 g/mol.

In addition to the active ingredient, the tablets contain various inactive ingredients (excipients) that serve important functions in the manufacturing, stability, and performance of the tablet. Common excipients used in lacosamide film-coated tablets include:

• Tablet core: Microcrystalline cellulose (filler/binder), hydroxypropylcellulose (binder), crospovidone (disintegrant), magnesium stearate (lubricant), and colloidal anhydrous silica (glidant).
• Film coating: Polyvinyl alcohol, titanium dioxide (E171, colorant), macrogol (polyethylene glycol, plasticizer), talc (anti-tacking agent), and may contain iron oxide yellow (E172) or iron oxide red (E172) depending on the tablet strength for color differentiation.

Lacosamide Medical Valley tablets are designed as film-coated tablets, meaning they have a thin polymeric coating around the tablet core. This coating serves multiple purposes: it makes the tablet easier to swallow, provides protection from moisture and light, masks any unpleasant taste of the active ingredient, and can improve tablet stability. The different strengths of lacosamide tablets are typically color-coded for easy identification — for example, 50 mg tablets are usually a light pink color, while higher strengths have different colors to prevent dosing errors.

Patients with known allergies or intolerances to any of the listed excipients should inform their healthcare provider before starting treatment. The tablets do not contain lactose, gluten, or sucrose, making them suitable for patients with common food intolerances.